Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Epigenetics|September 6, 2016
Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinomaBenjamin Goeppert, Christina Ernst, Constance Baer, et al.
Annals of Surgery|June 25, 2021
Distal Bile Duct Cancer: Radical (R0 > 1 mm) Resection Achieves Favorable SurvivalChristine Tjaden, Ulf Hinz, Ulla Klaiber, et al.
JHEP Reports : Innovation in Hepatology|October 4, 2023
JNKs protect from cholestatic liver disease progression by modulating Apelin signallingMohamed Ramadan Mohamed, Johannes Haybaeck, Hanghang Wu, et al.
Ebiomedicine|June 22, 2023
DNA methylation-based classifier differentiates intrahepatic pancreato-biliary tumoursMihnea P Dragomir, Teodor G Calina, Eilís Perez, et al.
BMC Cancer|May 2, 2021
Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samplesKatharina Kriegsmann, Christiane Zgorzelski, Thomas Muley, et al.
The European Respiratory Journal|August 31, 2013
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotypeArne Warth, Roland Penzel, Heike Lindenmaier, et al.
Cancers|March 10, 2022
STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular CarcinomaCarolin Ploeger, Johannes Schreck, Thorben Huth, et al.
Cancers|September 9, 2020
RNA Sequencing of Hepatobiliary Cancer Cell Lines: Data and Applications to Mutational and Transcriptomic ProfilingDominique Scherer, Marcela Dávila Dávila López, Benjamin Goeppert, et al.
BMC Cancer|January 17, 2019
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodiesMark Kriegsmann, Stephanie Roessler, Katharina Kriegsmann, et al.
Cancers|January 21, 2022
HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1Stefanie Schuller, Jan Sieker, Philip Riemenschneider, et al.
Pageof 13